

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/774,319	01/31/2001	Richard A. Gambale	B0410/7269D1	2488
75	90 02/26/2002			
John F. Perullo Kirkpatrick & Lockhart LLP 75 State Street			EXAMINER	
			KENNEDY, SHARON E	
Boston, MA 02109-1808			ART UNIT	PAPER NUMBER
			3763	
			DATE MAILED: 02/26/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/774,319

Applicant(s)

Gambale et al.

Examiner

Sharon Kennedy

Art Unit **3763** 



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
A SHOTHE N - Exter aft - If the be - If NO co - Failur - Any r ea  Status 1)	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. Usions of time may be available under the provisions of 37 Cler SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) days considered timely.  period for reply is specified above, the maximum statutory period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by eply received by the Office later than three months after the red patent term adjustment. See 37 CFR 1.704(b).  Responsive to communication(s) filed on	TO EXPIRE MONTH(S) FROM  FR 1.136 (a). In no event, however, may a reply be timely filed ation.  The area of a reply within the statutory minimum of thirty (30) days will experied will apply and will expire SIX (6) MONTHS from the mailing date of this extatute, cause the application to become ABANDONED (35 U.S.C. § 133).  The mailing date of this communication, even if timely filed, may reduce any
2a) □	This action is <b>FINAL</b> . 2b)  This act	
3}∟	closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 💢	Claim(s) <u>20-31</u>	is/are pending in the application.
4	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 🗆	Claim(s)	is/are rejected.
7) 🗆	Claim(s)	
8) 💢	Claims <u>20-31</u>	are subject to restriction and/or election requirement.
9) 🗆 10) 🗆 11) 🗆	tion Papers The specification is objected to by the Examiner. The drawing(s) filed on is/are The proposed drawing correction filed on The oath or declaration is objected to by the Exami	is: a)□ approved b)□ disapproved.
Priority	under 35 U.S.C. § 119	
13) 🗆	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).
a) L		
	1. Certified copies of the priority documents have	
	,	e been received in Application No  ocuments have been received in this National Stage
	application from the International Bure the attached detailed Office action for a list of the	au (PCT Rule 17.2(a)).
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
Attachm	ent(s)	
_	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) 🔲 Int	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:

Application/Control Number: 09/774,319

Art Unit: 3763

## **DETAILED ACTION**

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 20-29, drawn to a method of promoting angiogenesis, classified in class
     604, subclass 502.
  - II. Claim 30, drawn to a delivery device, classified in class 604, subclass 264.
  - III. Claim 31, drawn to a method of delivering an implant, classified in class 604, subclass 506.
- 2. The inventions are distinct, each from the other because:
- 3. Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used to deliver other implants, such as intrauterine devices.
- 4. Inventions I and (II and III) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions. One is a method of promoting angiogenesis and one is a method or apparatus for delivering an implant to myocardial tissue.

Application/Control Number: 09/774,319

Art Unit: 3763

5. This application contains claims directed to the following patentably distinct species of the claimed invention:

Species 1: Figures 1A-1B

Species 2: Figures 1C-1D

Species 3: Figures 4A-4D

Species 4: Figures 5A-5C

Species 5: Figures 7A-8B

Species 6: Figures 10A-10B

Species 7: Figures 12A-12D

Species 8: Figure 13

Species 9: Figures 15A-15D

Species 10: Figures 17A-17D

Species 11: Figures 19A-19E

Species 12: Figures 19F-19G

- 6. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claim is generic.
- 7. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable

Application/Control Number: 09/774,319

Art Unit: 3763

Page 4

thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

- 8. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).
- 9. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 10. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon Kennedy whose telephone number is (703) 305-0154.

Maron Kennedy Sharon Kennedy Primary Examiner